Enrollment insights in the synchronous mRCC population: An update from the ongoing ADAPT* phase 3 study experience. Background: Pazopanib is an oral, selective, multikinase inhibitor of VEGF receptors ...
The SGLT2 inhibitors, as a class, lead to similar treatment benefits at comparable clinical doses, although there are some discrepancies between them, particularly when dapagliflozin (Farxiga; ...
Comparative effectiveness research increasingly is being recognized as a priority area in cancer research. Although researchers have been conducting comparative effectiveness research for decades, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results